$DROR
Dror Ortho-Design, Inc.

2024 Q3 Form 10-Q Financial Statement

#000121390024069044 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $81.27K
YoY Change 120.48%
% of Gross Profit
Research & Development $451.0K $389.2K $349.6K
YoY Change 82.58% 11.34%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.302M $1.497M $81.27K
YoY Change 134.39% 1742.02% 120.48%
Operating Profit -$1.302M -$1.497M -$81.27K
YoY Change 134.39% 1742.02% 120.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$525.2K -$9.872K
YoY Change -28894.46%
Pretax Income -$1.827M -$1.507M -$81.27K
YoY Change 230.05% 1754.17% 120.48%
Income Tax
% Of Pretax Income
Net Earnings -$1.827M -$1.507M -$81.27K
YoY Change 230.05% 1754.17% 120.48%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 495.5M shares 495.5M shares 202.3M shares
Diluted Shares Outstanding 738.3M shares 495.5M shares 202.3M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.22K
YoY Change -78.21%
Cash & Equivalents $1.143M $1.834M $27.22K
Short-Term Investments
Other Short-Term Assets $1.960K
YoY Change 6.52%
Inventory
Prepaid Expenses $1.959K
Receivables
Other Receivables
Total Short-Term Assets $1.242M $1.895M $29.18K
YoY Change -70.16% 6394.15% -76.98%
LONG-TERM ASSETS
Property, Plant & Equipment $25.38K $26.61K
YoY Change 916.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $25.38K $26.61K $0.00
YoY Change 916.71%
TOTAL ASSETS
Total Short-Term Assets $1.242M $1.895M $29.18K
Total Long-Term Assets $25.38K $26.61K $0.00
Total Assets $1.267M $1.921M $29.18K
YoY Change -69.57% 6485.37% -76.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $84.68K $94.34K $176.0K
YoY Change 1353.48% -46.38% 77.17%
Accrued Expenses $592.00
YoY Change 0.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $887.9K $257.9K $884.7K
YoY Change -9.47% -70.85% 16.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $5.126K
YoY Change 1248.95%
Total Long-Term Liabilities $5.126K $0.00
YoY Change 1248.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $887.9K $257.9K $884.7K
Total Long-Term Liabilities $5.126K $0.00
Total Liabilities $893.0K $263.0K $884.7K
YoY Change -8.98% -70.27% 16.71%
SHAREHOLDERS EQUITY
Retained Earnings -$18.37M -$16.55M -$41.94M
YoY Change 60.21% -60.54% 0.54%
Common Stock $95.70K $49.55K $41.08M
YoY Change 93.16% -99.88% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $374.5K $1.658M -$855.5K
YoY Change
Total Liabilities & Shareholders Equity $1.267M $1.921M $29.18K
YoY Change -69.57% 6485.37% -76.98%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.827M -$1.507M -$81.27K
YoY Change 230.05% 1754.17% 120.48%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$16.14K
YoY Change -27.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K
YoY Change
NET CHANGE
Cash From Operating Activities -16.14K
Cash From Investing Activities 0.000
Cash From Financing Activities 20.00K
Net Change In Cash 3.860K
YoY Change -117.36%
FREE CASH FLOW
Cash From Operating Activities -$16.14K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106782187 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189063296 shares
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51783
dei Entity Registrant Name
EntityRegistrantName
Dror Ortho-Design, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0461778
dei Entity Address Address Line1
EntityAddressAddressLine1
Shatner Street 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Jerusalem
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
N/A
dei City Area Code
CityAreaCode
+972
dei Local Phone Number
LocalPhoneNumber
(0)74-700-6700
dei Security12b Title
Security12bTitle
None
dei No Trading Symbol Flag
NoTradingSymbolFlag
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
495454546 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1834477 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3347843 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
60192 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
114100 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1894669 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3461943 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26612 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2328 usd
CY2024Q2 us-gaap Assets
Assets
1921281 usd
CY2023Q4 us-gaap Assets
Assets
3464271 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
94338 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
106833 usd
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
163588 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
190271 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
257926 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
297104 usd
CY2024Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
5059 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
5243 usd
CY2024Q2 us-gaap Liabilities
Liabilities
262985 usd
CY2023Q4 us-gaap Liabilities
Liabilities
302347 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
12500000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
12500000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10463363 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10463363 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
1047 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
1047 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3254475740 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
495454546 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
495454546 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
495454546 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
495454546 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
49545 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49545 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18153662 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
16842037 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16545958 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13730705 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1658296 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3161924 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1921281 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3464271 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
389216 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
140590 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
762873 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
439362 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
333274 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
151347 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
718838 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
316444 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
774428 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5088 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1311625 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10120 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1496918 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
297025 usd
us-gaap Operating Expenses
OperatingExpenses
2793336 usd
us-gaap Operating Expenses
OperatingExpenses
765926 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1496918 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-297025 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2793336 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-765926 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9872 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11243 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21917 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14540 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9872 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11243 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21917 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14540 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1506790 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-285782 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2815253 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-751386 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1506790 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-285782 usd
us-gaap Net Income Loss
NetIncomeLoss
-2815253 usd
us-gaap Net Income Loss
NetIncomeLoss
-751386 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
495454546 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
495454546 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3161924 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
537197 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1308463 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2390658 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
774428 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1506790 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1658296 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
596076 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5032 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-465604 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
135504 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5088 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-285782 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-145190 usd
us-gaap Net Income Loss
NetIncomeLoss
-2815253 usd
us-gaap Net Income Loss
NetIncomeLoss
-751386 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1311625 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10120 usd
us-gaap Depreciation
Depreciation
1565 usd
us-gaap Depreciation
Depreciation
335 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-53908 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
35168 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-12495 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-5923 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-26683 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
16149 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-240000 usd
us-gaap Increase Decrease In Postemployment Obligations
IncreaseDecreaseInPostemploymentObligations
-184 usd
us-gaap Increase Decrease In Postemployment Obligations
IncreaseDecreaseInPostemploymentObligations
-21 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1487517 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1005894 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25849 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25849 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1513366 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1005894 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3347843 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1039059 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1834477 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33165 usd
CY2023Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
106782187 shares
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16545958 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates or assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could vary from those estimates. Management utilizes various other estimates, including but not limited to accrued royalties, accrued expenses, the valuation of stock-based compensation, the valuation allowance for deferred tax assets and other contingencies. The results of any changes in accounting estimates are reflected in the financial statements in the period in which the changes become evident. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that they are determined to be necessary.</p>
CY2024Q2 dror Currency Exchange Rate
CurrencyExchangeRate
3.759
CY2023Q4 dror Currency Exchange Rate
CurrencyExchangeRate
3.627
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
145168 usd
CY2024Q2 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
100 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
975288919 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
510794865 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
184264323 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
163142084 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2205889541 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1431636849 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reclassification</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative expenses totaling $38,662 and $5,088 for the three months ended June 30, 2023, and $97,042 and $10,120 for the six months ended June 30, 2023, were reclassified to research and development and share-based compensation, respectively, to conform with current period presentation. The reclassifications had no effect on the net loss for the six months ended June 30, 2023.</p>
dror Percentage Of Royalty Payment
PercentageOfRoyaltyPayment
0.03 pure
dror Maximum Percentage Of Grants Provided For Royalty Payment
MaximumPercentageOfGrantsProvidedForRoyaltyPayment
1 pure
CY2024Q2 us-gaap Other Commitment
OtherCommitment
1160000 usd
CY2023Q4 us-gaap Other Commitment
OtherCommitment
1120000 usd
us-gaap Product Liability Contingency Third Party Recovery Percentage
ProductLiabilityContingencyThirdPartyRecoveryPercentage
0.01 pure
dror Liquidated Bear Interest Rate
LiquidatedBearInterestRate
0.18 pure
dror Investors Percentage
InvestorsPercentage
0.501 pure
us-gaap Product Liability Contingency Loss Exposure Not Accrued Best Estimate
ProductLiabilityContingencyLossExposureNotAccruedBestEstimate
520000 usd
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
240000 usd
CY2024Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common Stock are entitled to vote on a 1 share/1 vote basis
dror Warrants To Be Expired
WarrantsToBeExpired
20960439 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
18181817 shares
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.033
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
35814 usd
dror Exercise Price Of The Warrants Percentage
ExercisePriceOfTheWarrantsPercentage
3 pure
dror Minimum Trading Volume Of Common Stock Each Trading Day Condition For Warrant Redemption
MinimumTradingVolumeOfCommonStockEachTradingDayConditionForWarrantRedemption
500000 usd
dror Warrant Redemption Price Per Share
WarrantRedemptionPricePerShare
0.001
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
21122239 shares
CY2024Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.0037
CY2024Q2 dror Vested Immediately Grant And Terminate
VestedImmediatelyGrantAndTerminate
P10Y
CY2024Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
170920 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
774428 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5088 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1311625 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10120 usd
CY2023Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
3651 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
992768 usd
CY2024Q2 dror Share Based Compensation Relating To Research And Development Expenses
ShareBasedCompensationRelatingToResearchAndDevelopmentExpenses
163734 usd
CY2023Q2 dror Share Based Compensation Relating To Research And Development Expenses
ShareBasedCompensationRelatingToResearchAndDevelopmentExpenses
1437 usd
dror Share Based Compensation Relating To Research And Development Expenses
ShareBasedCompensationRelatingToResearchAndDevelopmentExpenses
318857 usd
dror Share Based Compensation Relating To Research And Development Expenses
ShareBasedCompensationRelatingToResearchAndDevelopmentExpenses
2857 usd
CY2022Q2 dror Consideration Amount
ConsiderationAmount
3500 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2610 shares
CY2022Q2 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
9597675 shares
CY2024Q1 us-gaap Payments For Fees
PaymentsForFees
5000 usd
CY2024Q1 us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
55000 usd
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
145000 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10454500 shares
CY2023Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.033
CY2023Q3 us-gaap Dividends Share Based Compensation Cash
DividendsShareBasedCompensationCash
14500 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2024-07-15
CY2024Q2 us-gaap Product Warranty Liquidation Proceeds Amount
ProductWarrantyLiquidationProceedsAmount
35814 usd
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
495454546 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
495454546 shares
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001282980

Files In Submission

Name View Source Status
dror-20240630_cal.xml Edgar Link unprocessable
0001213900-24-069044-index-headers.html Edgar Link pending
0001213900-24-069044-index.html Edgar Link pending
0001213900-24-069044.txt Edgar Link pending
0001213900-24-069044-xbrl.zip Edgar Link pending
dror-20240630.xsd Edgar Link pending
ea0211157-10q_drorortho.htm Edgar Link pending
ea021115701ex31-1_drorortho.htm Edgar Link pending
ea021115701ex31-2_drorortho.htm Edgar Link pending
ea021115701ex32-1_drorortho.htm Edgar Link pending
ea021115701ex32-2_drorortho.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
dror-20240630_def.xml Edgar Link unprocessable
dror-20240630_lab.xml Edgar Link unprocessable
dror-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0211157-10q_drorortho_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending